Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AEON Biopharma ( (AEON) ) just unveiled an announcement.
On September 8, 2025, AEON Biopharma, Inc. released a corporate presentation on its website, which may be used by management in future meetings. This presentation is part of a current report on Form 8-K and is not considered filed under the Securities Exchange Act of 1934, nor incorporated by reference in any filing under the Securities Act of 1933.
The most recent analyst rating on (AEON) stock is a Buy with a $360.00 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.
Spark’s Take on AEON Stock
According to Spark, TipRanks’ AI Analyst, AEON is a Underperform.
AEON Biopharma is under significant financial distress, with negative profitability and cash flow challenges. While technical indicators show some stabilization, the overall bearish trend persists. The lack of profitability and absence of dividends weigh heavily on its valuation. The neutral earnings call impact slightly offsets these negatives but is insufficient to improve the overall outlook.
To see Spark’s full report on AEON stock, click here.
More about AEON Biopharma
AEON Biopharma, Inc. operates in the biopharmaceutical industry, focusing on developing advanced therapies for various medical conditions.
Average Trading Volume: 180,166
Technical Sentiment Signal: Sell
Current Market Cap: $8.89M
For an in-depth examination of AEON stock, go to TipRanks’ Overview page.